Featured Research

from universities, journals, and other organizations

Zeroing In On RNA-binding In Myotonic Dystrophy

Date:
November 13, 2007
Source:
University of Oregon
Summary:
Researchers have shed new light on the function of an RNA-regulating protein known as muscleblind, which when it misbehaves and binds to rogue RNA can lead to disease affecting roughly one in 8,000 people.

University of Oregon researchers Andy Berglund, left, and his doctoral student Bryan Warf have found clues that may trigger the onset of myotonic dystrophy symptoms.
Credit: Jim Barlow

University of Oregon researchers have shed new light on the function of an RNA-regulating protein known as muscleblind, which when it misbehaves and binds to rogue RNA can lead to disease affecting roughly one in 8,000 people.

Related Articles


The study, which used a combination of biochemical, biophysical and cell culture studies, was placed online ahead of regular publication in the December issue of the journal RNA. When the findings were initially presented in September at the annual meeting of the Myotonic Dystrophy Foundation in Italy, the work garnered a $1,000 cash prize for outstanding research for lead author Bryan Warf, a UO doctoral student.

Misbehaving RNA can lead to myotonic dystrophy, an inherited condition that affects muscles and other body systems. It is the most commonly occurring form of adult onset muscular dystrophy with progressive muscle wasting as well as a variety of symptoms. An early symptom is the inability of muscles to relax after a simple handshake or gripping of a doorknob. It also can lead to cataracts, cardiac arrhythmia, insulin resistance and male infertility. It can be life-threatening in cases of early onset, particularly in children. Researchers believe that the numbers of a specific type of nucleotide expansions in a person's DNA gives rise to myotonic dystrophy.

The UO findings apply to both known forms: DM1, which can manifest at any point in life, from birth to late 60s; and DM2, which more commonly surfaces in adulthood. While independent genes are responsible in each form, the same protein's interaction with RNA in the genes is implicated in both diseases.

"In a simplistic view, this disease is about this protein not functioning properly," Warf said. "So we've been trying to see what this protein does normally to keep us healthy and promote healthy development."

In their study, Warf and Andy Berglund, professor of chemistry and member of the Institute of Molecular Biology, focused on the RNA-splicing protein muscleblind-like (MBNL) and its interactions with both normal strands of RNA and disease-causing RNA that contains mismatched pairs of repeat nucleotides. RNA (ribonucleic acid) is much like translation software, a driver that serves as a messenger between DNA and proteins.

"Toxic RNA," as Berglund describes the mutated strands in the genome, is like a sentence that contains many extra misplaced copies of the word "the" within it. In their paper, Warf and Berglund found that MBNL binds to both normal and toxic forms of RNA. When bound to the toxic versions, MBNL ignores its other RNA targets and does not help process them normally, leading to disease. In earlier work, Berglund's lab solved the crystal structure of the toxic RNA.

In this new study, Warf and Berglund tested MBNL's interactions with both normal RNA and toxic RNA. They found that muscleblind has no preference for a toxic RNA that contains any type of pyrimidine-pyrimidine mismatch. Warf and Berglund were the first to articulate the structure of one of MBNL's normal RNA targets. It had been thought that the structure of the toxic RNA was much different than the structure of a normal RNA target for MBNL, but Warf and Berglund showed that the two structures are actually quite similar.

"Through his studies," Berglund said, "Bryan has provided insight into how muscleblind may normally function. The dogma was that this protein was recognizing a complex structure in the toxic RNA, and normally it was recognizing a more simple RNA structure in regulating splicing. Bryan found the RNA that is normally recognized actually adopts a structure that looks a lot like the toxic RNA. Muscleblind recognizes both. The diseased RNA is mimicking the natural RNA."

The work was funded by a grant to Berglund from the Muscular Dystrophy Association, grants from the National Institutes of Health to Berglund and to Warf's co-adviser Peter H. von Hippel, professor of biophysical chemistry and molecular biology, and an NIH training grant to the UO Institute of Molecular Biology.


Story Source:

The above story is based on materials provided by University of Oregon. Note: Materials may be edited for content and length.


Cite This Page:

University of Oregon. "Zeroing In On RNA-binding In Myotonic Dystrophy." ScienceDaily. ScienceDaily, 13 November 2007. <www.sciencedaily.com/releases/2007/11/071107160148.htm>.
University of Oregon. (2007, November 13). Zeroing In On RNA-binding In Myotonic Dystrophy. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2007/11/071107160148.htm
University of Oregon. "Zeroing In On RNA-binding In Myotonic Dystrophy." ScienceDaily. www.sciencedaily.com/releases/2007/11/071107160148.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins